ClinicaliQ Trial Snapshot
- Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency — Recruiting • Phase III • NCT07266805.
- Trial testing oral deucrictibant tablets to prevent and treat angioedema attacks in adults with C1 inhibitor deficiency.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant IR capsule for on-demand treatment of angioedema attacks in adult participants aged ≥ 18 years with AAE-C1INH. Conditions: Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) Interventions: Deucrictibant, Placebo, Deucrictibant, Placebo, Deucrictibant Lead Sponsor: Pharvaris Netherlands B.V. Planned Enrollment: 32 participants